Dietary medium-chain triacylglycerols in metabolic regulation.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways and clinical literature without systematic methodology.
PubMed 41115818 · doi:10.1016/j.tem.2025.09.010
What was done
The authors synthesized existing literature on dietary medium-chain triacylglycerols (MCTs; C8:0–C12:0) to review their distinct absorption pathways and metabolic impacts on cardiometabolic health, cellular substrate partitioning, mitochondrial dynamics, and gut-liver signaling.
What was found
No numerical findings or effect sizes are reported in the abstract. Qualitatively, MCTs enter the portal circulation directly as free fatty acids and are largely metabolized to ketone bodies in the liver. The literature links MCT consumption to enhanced glucose homeostasis, increased energy expenditure, greater satiety, modest weight reduction, chain length-dependent changes in circulating lipoprotein profiles and liver metabolism, and potential benefits for cardiac contractility.
Why it matters
This review integrates mechanistic pathways and cardiometabolic associations of MCTs, helping clarify how differing fatty acid chain lengths influence human energy expenditure and substrate utilization.
Limits
The abstract reports no quantitative data, effect sizes, or study counts. Because this is a narrative review rather than a systematic review, it lacks formal risk-of-bias grading and may combine animal, in vitro, and human evidence without clear separation.